• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Biomedical sciences publications August 1, 2015

Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis

Citation

Copy to clipboard


Leung, T., Bergen, A., Munafo, M. R., De Ruyck, K., Selby, P., & De Luca, V. (2015). Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis. Pharmacogenomics, 16(7), 713-720.

Abstract

Objective

To assess if the allelic variations of rs16969968/rs1051730 in the CHRNA5-CHRNA3-CHRNB4 gene cluster are associated with smoking cessation after nicotine replacement therapy (NRT).

Methods

We searched for NRT studies published from 2000-2013 that reported counts for allelic variation of rs16969968/rs1051730 and measured abstinence rates at the end of NRT treatment. We identified four studies which met the criteria, giving us a test sample of 2036 participants.

Results

There was no effect of rs16969968/rs1051730 in influencing the success rate at the end of NRT (n = 6, effect size [ES]: 0.969, 95% CI: 0.77 to 1.23, z = 0.27, p = 0.791).

Conclusion

There is no robust evidence that allelic variations of rs16969968 or rs1051730 are associated with smoking cessation after NRT. Original submitted 26 November 2014; Revision submitted 9 March 2015.

↓ View online

Share this

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International